• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Stryker Biotech to pay $1.35 million to settle Bay State beef

Stryker Biotech to pay $1.35 million to settle Bay State beef

August 26, 2010 By MassDevice staff

SYK logo

It took less than 24 hours for Stryker Corp. (NYSE:SYK) to settle a lawsuit filed against its Bay State-based biotech division by Mass. attorney general Martha Coakley for $1.35 million.

Coakley sued Hopkinton, Mass.-based Stryker Biotech yesterday, accusing the firm of illegally promoting the combined use of a pair of its bone growth products and of falsifying Institutional Review Board documents. A settlement, announced this morning, will see Stryker pay $325,000 in civil penalties, $875,000 into an anti-false marketing and consumer protection fund and $150,000 in legal and investigative costs. In a statement emailed late in the day Aug. 27, Stryker said the settlement “does not include any admission of liability.”

The lawsuit accused the company of "subverting clinical and medical review procedures designed to protect patient safety" in falsifying the IRB documents, promoting the use of products in applications not approved by the Food & Drug Administration and "failing to disclose information to Massachusetts physicians and medical professionals about restrictions imposed on the use of its products," according to the complaint.

The case involves separate bone-healing products, each granted a narrow, provisional “humanitarian device exemption” by the FDA. Stryker and four former executives are also fighting a federal beef for allegedly promoting the combination of its OP-1 Implant, OP-1 Putty and the bone void filler Calstrux.

Former Stryker Biotech president Mark Philip and sales managers David Ard, Jeff Whitaker and William Heppner, were indicted by a grand jury on charges of wire fraud and conspiracy. Stryker and Philip were also charged with making false statements to the FDA. Heppner was the company’s national sales director; Ard and Whitaker were regional managers for the western and central territories, respectively.

The federal indictment charges that Stryker and Philip lied to the FDA about the number of patients treated each year with OP-1 Putty. According to a regulatory filing, "certain former Stryker Biotech employees have pled guilty to charges in connection with this matter." If Stryker is found guilty, it could be excluded from "participating in federal and state health care programs, which could have a material effect on Stryker Biotech’s business," according to the filing.

Calls and emails to Stryker seeking comment were not immediately returned.

Filed Under: Business/Financial News, Legal News, News Well, Orthopedics Tagged With: Stryker

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy